MINNEAPOLIS--(BUSINESS WIRE)--Medtronic (NYSE:MDT) today announced that data reviewed by an independent physician panel – using new, broader definitions for evaluating stent thrombosis – confirms that the Endeavor® drug-eluting stent (DES) has a very low rate of stent thrombosis. The independent panel will present detailed findings of this retrospective analysis during a special drug-eluting stent safety session later today at the Cardiovascular Research Foundation’s (CRF) 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.
